When does Sangamo report earnings and how could that affect SGMO stock?

Sangamo reports on 18 Mar 2026 at 16:00 EDT (20:00 UTC). Results and guidance on cash and trials can swing SGMO stock intraday; positive trial updates or better cash outlook usually lift the shares, while funding needs or delays can push them lower

What are the main risks for SGMO stock after earnings?

Primary risks are negative EPS **-0.45**, limited cash per share **0.10**, and high R&D burn. Clinical setbacks or increased financing needs are immediate downside drivers for SGMO stock

How does Meyka AI view SGMO stock value and forecast?

Meyka AI assigns SGMO a **B (69.52)** grade with a HOLD suggestion and forecasts a monthly model value of **$0.08**. This is a model projection and not a guarantee; it implies significant downside versus **$0.36**

Are analysts generally bullish or bearish on SGMO stock?

Consensus shows 4 buys and no holds or sells on the available coverage, indicating analyst optimism. Yet market pricing reflects clinical and financing risk, so analyst views may diverge from near-term trading in SGMO stock

US Stocks

Sangamo Therapeutics (SGMO) NASDAQ US 18 Mar 2026: Market closed, earnings tonight

ByDanny Kontos March 19, 2026March 19, 2026

SGMO stock closed at $0.36 on NASDAQ in the United States on 18 Mar 2026 as investors wait for tonight’s Q4 earnings announcement at 16:00 EDT (20:00 UTC). We see heightened volume at 8,305,912.00 shares and a day range of $0.36–$0.39, reflecting short-term pressure after a -5.26% intraday move. Sangamo Therapeutics, Inc. (SGMO) reports amid a thin cash runway, negative EPS of -0.45, and clinical readouts that could swing sentiment. This earnings spotlight highlights guidance, cash use, and clinical milestones that will drive SGMO stock in the next 24–72 hours